Assay for Detecting Collagen XI Biomarkers
US-2024085428-A1 · Mar 14, 2024 · US
Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
US11112413B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11112413-B2 |
| Application number | US-201816123750-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 6, 2018 |
| Priority date | Mar 8, 2016 |
| Publication date | Sep 7, 2021 |
| Grant date | Sep 7, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed to epitope-tagged antibodies, as well as methods of employing the epitope-tagged antibodies for detecting one or more targets in a biological sample, e.g. a tissue sample.
First claim
Opening claim text (preview).
The invention claimed is: 1. A kit comprising: (a) at least one epitope-tagged antibody, wherein the at least one epitope-tagged antibody comprises an antibody and at least one epitope tag construct, and (b) detection reagents for detecting the at least one epitope-tagged antibody, wherein the detection reagents comprise at least one anti-tag antibody, wherein the at least one anti-tag antibody is specific for an expressed epitope tag of the at least one epitope-tagged antibody, and wherein the at least one epitope tag construct consists of the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32. 2. The kit of claim 1 , wherein the at least one anti-tag antibody comprises a fluorophore. 3. The kit of claim 1 , wherein the at least one epitope-tagged antibody comprises at least one epitope-tagged antibody specific for FoxP3, at least one epitope-tagged antibody specific for CD8, at least one epitope-tagged antibody specific for CD68, at least one epitope-tagged antibody specific for CD3, and at least one epitope-tagged antibody specific for CD20. 4. The kit of claim 1 , wherein the at least one epitope tag construct is expressed at a terminal end of a heavy chain antibody. 5. The kit of claim 1 , wherein the at least one epitope-tagged antibody is specific for the antigen human FoxP3. 6. The kit of claim 5 , wherein the at least one epitope tag construct consists of the amino acid sequence of SEQ ID NO:22. 7. The kit of claim 1 , further comprising instructions for use.
Assignees
Inventors
Classifications
against the T-cell receptor (TcR)-CD3 complex · CPC title
against B7 molecules, e.g. CD80, CD86 · CPC title
against translation products of oncogenes · CPC title
against CD8 · CPC title
containing a tag for immunodetection, or an epitope for immunisation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11112413B2 cover?
- The present disclosure is directed to epitope-tagged antibodies, as well as methods of employing the epitope-tagged antibodies for detecting one or more targets in a biological sample, e.g. a tissue sample.
- Who is the assignee on this patent?
- Ventana Med Syst Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6878. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).